The NOV Supernova Accelerator will work to cultivate relationships between startups and NOV. Photo via Getty Images

Houston-based Venture Builder VC has kicked off its NOV Supernova Accelerator and named its inaugural cohort.

The program, originally announced earlier this year, focuses on accelerating digital transformation solutions for NOV Inc.'s operations in the upstream oil and gas industry. It will support high-potential startups in driving digital transformation within the energy sector, specifically upstream oil and gas, and last five months and culminate in a demo day where founders will present solutions to industry leaders, potential investors, NOV executives, and other stakeholders.

The NOV Supernova Accelerator will work to cultivate relationships between startups and NOV. They will offer specific companies access to NOV’s corporate R&D teams and business units to test their solutions in an effort to potentially develop long-term partnerships.

“The Supernova Accelerator is a reflection of our commitment to fostering forward-thinking technologies that will drive the future of oil and gas,” Diana Grauer, director of R&D of NOV, says in a news release.

The cohort’s focus will be digital transformation challenges that combine with NOV’s vision and include data management and analytics, operational efficiency, HSE (Health, Safety, and Environmental) monitoring, predictive maintenance, and digital twins.

Startups selected for the program include:

  • AnyLog, an edge data management platform that replaces proprietary edge projects with a plug-and-play solution that services real-time data directly at the source, eliminating cloud costs, data transfer, and latency issues.
  • Equipt, an AI-powered self-serve platform that maximizes Asset & Field Service performance, and minimizes downtime and profit leakages.
  • Geolumina's platform is a solution that leverages data analytics to enhance skills, scale insights, and improve efficiency for subsurface companies.
  • Gophr acts as the "Priceline" of logistics, using AI to provide instant shipping quotes and optimize dispatch for anything from paper clips to rocket ships.
  • IoT++ simplifies industrial IoT with a secure, AI-enabled ecosystem of plug-and-play edge devices.
  • Kiana's hardware-agnostic solution secures people, assets, and locations using existing Wi-Fi, Bluetooth, UWB, and cameras, helping energy and manufacturing companies reduce risks and enhance operations.
  • Novity uses AI and physics models to accurately predict machine faults, helping factory operators minimize downtime by knowing the remaining useful life of their machines.
  • Promecav is redefining crude oil conditioning with patented technology that slashes water use and energy while reducing toxic exposure for safer, cleaner, and more sustainable oil processing.
  • RaftMind's enterprise AI solution transforms how businesses manage knowledge. Our advanced platform makes it easier to process data and unlock insights from diverse sources.
  • Spindletop AI uses edge-based machine learning to make each well an autonomous, self-optimizing unit, cutting costs, emissions, and cloud dependence.
  • Taikun.aicombines generative AI with SCADA data to create virtual industrial engineers, augmenting human teams for pennies an hour.
  • Telemetry Insight’s platform utilizes high-resolution accelerometer data to simplify oilfield monitoring and optimize marginal wells for U.S. oil and gas producers via actionable insights.
  • Visual Logging utilizes fiber optic and computer vision technology to deliver real-time monitoring solutions, significantly enhancing data accuracy by providing precise insights into well casing integrity and flow conditions.

“Each startup brings unique solutions to the table, and we are eager to see how these technologies will evolve with NOV’s support and expertise,” Billy Grandy, general partner of Venture Builder VC, says in the release. “This partnership reflects our ongoing commitment to nurturing talent and driving innovation within the energy sector.”

Venture Builder VC is a consulting firm, investor, and accelerator program.

“Unlike mergers and acquisitions, the venture client model allows corporations like NOV to quickly test and implement new technologies without committing to an acquisition or risking significant investment,” Grandy previously said about the accelerator program.

------

This article originally ran on EnergyCapital.

The two entities will combine resources and efforts to "drive innovation, accelerate growth and empower young companies." Photo via Getty Images

2 Houston organizations team up to drive SaaS innovation within energy sector

howdy, partner

Two entities looking to support software-as-a-service innovation have teamed up on a new resource to meet the energy sector corporate clients' growing technology demands.

MOIC Partners, an energy enterprise software sales support solution provider founded earlier this year, and Venture Builder VC, a consulting firm, investor, and accelerator program operator led by a group of Houston innovators, have announced a new partnership. The two entities will combine resources and efforts to "drive innovation, accelerate growth and empower young companies," per a news release from the organizations.

“Throughout our careers, we’ve encountered various approaches to achieving the broader innovation objectives of Venture Builder VC and, in our judgment, this program truly stands out as a model that has the potential to introduce significant innovation to the energy sector in an abbreviated timeframe,” Dave Levitt of MOIC Partners says in the release.

MOIC Partners provides go-to-market products and services, including MOIC Sales Engine, MOIC Pipeline Grader, MOIC Pricing Engine, Virtual Dave, and MOIC Exit Engine.

Venture Builder VC recently partnered with NOV on a custom accelerator for the energy leader.

“We deliver disruptive solutions to enterprise R&D and innovation leaders by targeting growth-stage startups solving their specific problems," Billy Grandy, founder and general partner of Venture Builder VC, says in the release. "While founder-led models excel in driving change, they often struggle with scalability and change management with corporate customers. Our partnership with MOIC Partners provides essential tools to help small and mid-sized SaaS companies overcome these challenges and achieve sustainable growth.”

The five-month program establishes a significant relationship between the 20 selected startups and NOV, beginning with paid pilot programs. Photo via NOV.com

Houston energy company opens applications for unique energy tech startup pilot program

calling all innovators

Houston-based NOV is launching a new growth-stage startup accelerator focused on the upstream oil and gas industry.

NOV, a provider of oil and gas drilling and production operations equipment, has announced its new NOV Supernova Accelerator in collaboration with VentureBuilder, a consulting firm, investor, and accelerator program operator led by a group of Houston innovators.

Applications to the program are open online, and the deadline to apply is July 7. Specifically, NOV is looking for companies working on solutions in data management and analytics, operational efficiency, HSE monitoring, predictive maintenance, and digital twins.

The five-month program establishes a significant relationship between the 20 selected startups and NOV, beginning with paid pilot programs.

"This is not a traditional startup accelerator. This is often a first-client relationship to help disruptive startups refine product-market fit and creatively solve our pressing enterprise problems," reads the program's website.

Selected startups will have direct access to NOV's team and resources. The program will require companies to spend one week per month in person at NOV headquarters in Houston and will provide support surrounding several themes, including go-to-market strategy, pitch practice, and more.

“The NOV Supernova Accelerator offers a strategic approach where the company collaborates with startups in a vendor-client relationship to address specific business needs," says Billy Grandy, general partner of VentureBuilder.vc, in a statement. "Unlike mergers and acquisitions, the venture client model allows corporations like NOV to quickly test and implement new technologies without committing to an acquisition or risking significant investment.”

------

This article originally ran on EnergyCapital.

The Texas Medical Center has named its second cohort for its United Kingdom-focused health tech accelerator. Photo via TMC

16 digital health, medical device companies selected for UK, TMC accelerator

coming to Hou

For the second time, an accelerator backed by the United Kingdom and hosted by Texas Medical Center Innovation has named 16 companies to its new cohort.

In partnership with Innovate UK, TMC named the new cohort companies in an announcement this week. The companies are divided into two categories — digital health and medical device — and cover a wide range of specialties, from diagnostics and AI monitoring to non-surgical management and more.

The accelerator launched last year with its inaugural cohort with the mission of helping companies make their United States expansion by way of the TMC.

"The first cohort of startups in our accelerator program experienced TMC's capabilities in developing and advancing solutions through cross-collaboration with top minds in clinical care, commercialization and innovation," Devin Dunn, head of the Accelerator for Health Tech at TMC, says in a news release. "We are excited to continue our partnership with Innovate UK and welcome this second cohort to continue our efforts advancing life sciences technologies across the globe."

This year's program begins June 4 and will run through November. According to the TMC, last year's cohort had significant success tapping into the health tech ecosystem in Houston, including engaging with investors, setting up a go-to-market strategy, and making inaugural U.S.-based hires.

“Our Global Incubator Programme selects driven and ambitious innovators looking to scale their technologies globally," adds Jon Hazell, partnership manager for the North America and Global Incubator at Innovate UK. "We are excited for our second cohort of startups to join the programme, supported by the Texas Medical Center accelerator, where world-class mentors and programming will help our entrepreneurs understand and meet the requirements of different markets, and build the necessary partnerships, collaborations, and networks, facilitating their entry into global markets."

The selected medical device companies — and their technologies, as described by the TMC — include:

  • Cytecom – infectious diagnostic test, powered by cutting-edge optical electrophysiology, detects resistant bacteria in just 45 seconds, enabling doctors to prescribe targeted antibiotics in minutes instead of days
  • Heartfelt Technologies Ltd – the future of heart failure telemonitoring an automatic, AI supported, non-contact telemonitoring solution for heart failure patients
  • Neurovalens Ltd – creates wearable neurostimulaton devices that treat a range of conditions in an entirely non-invasive and drug-free way
  • Oxford Medical Products Limited – a proprietary hydrogel pill that acts as a non-surgical, non-pharmacological obesity treatment that will redefine the obesity treatment market
  • Phenutest – a rapid point-of-care diagnostic test for urinary tract infection, that confirms infection and appropriate antimicrobial to prescribe within 60 minutes
  • Plexaa – world's first fully wearable, sensor controlled, bra insert that can deliver safe supraphysiological preconditioning to the breast skin the night before surgery at home
  • SolasCure Limited – a wound Gel that acts as a single, effective and easy-to-use solution to overcome the challenges to transform chronic wound care
  • Trueinvivo Limited – a proprietary dosimetry (radiation measurement) system to ensure the precision and accuracy of cancer radiotherapy

The selected digital health companies — and their technologies, as described by the TMC — include:

  • Axon Diagnostics – offers a suite of solutions to support the needs of modern day diagnostic imaging services, supporting happier lives for clinicians and helping deliver better diagnostic care for all
  • Kheiron Medical Technologies – regarded as a world leader in the development of AI-enabled cancer diagnostics and monitoring
  • KiActiv – a technology-enabled digital health model for behaviour change and self-care that rethinks exercise and makes everyday movement an effective personalized medicine for better clinical outcomes
  • Memory Lane Games – turns memories into games, offering care providers a simple, fun dementia engagement app designed to trigger positive memories and improve socialisation with caregivers and people living with dementia
  • NeuroVirt Limited – combines immersive VR, AI and computer vision to gamify rehabilitation and quantify patient impairment and improvement
  • Newton’s Tree – enables healthcare providers to procure, integrate, and monitor third party AI products as part of routine care pathways through its enterprise AI platform
  • SERG Technologies – uses patented sensor technology and artificial intelligence to transform disease management into a continuous, data driven, and patient specific approach for people with Parkinson’s
  • Thymia – leverages speech, video, and behavioral analytics gathered via specially designed video games to diagnose conditions like depression, anxiety, and ADHD, alongside critical symptoms like fatigue, mood fluctuations, and memory issues, creating novel mental health biomarkers
The partnership between the U.K. and TMC began in 2018 as a biobridge between the two entities. TMC has expanded into new biobridges with other countries — most recently with The Netherlands — and also has a Danish accelerator that's also running its second cohort this summer.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.